ALAFY.PA Afyren SAS

Basic Materials Chemicals Euronext Paris
2.26 EUR
Close of Nov 8, 2026
2.07 3.24
Market cap
EUR 87.6M
P/E
-
P/B
1.22x
ROE
13.5%
Dividend yield
-
Fundamental score
1.0/5

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is ALAFY.PA undervalued?

Graham number

The Graham number of Afyren SAS cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Afyren SAS fundamental analysis

3 of 11 checks passed

ROE 0/2

The stock's ROE indicates a negative return (-12.36%) on shareholders' equity, suggesting poor financial performance.

ROA 0/2

The stock's ROA (-11.33%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

PBV 1/2

The stock's PBV ratio (1.11x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

DER 2/2

The stock has a minimal amount of debt (12%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

Revenue Growth 0/2

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

Net Profit Growth 0/2

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

Assets Growth 0/2

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

Graham Number 1/1

The Graham number analysis indicates that this company's stock price is likely undervalued, raising prospects for a favorable investment opportunity.

Dividend Growth 0/2

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

Dividend 0/2

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

Buffet Intrinsic Value 0/1

Warren Buffett's formula suggests that the company's stock is overpriced (-2), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Afyren SAS stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Afyren SAS

AFYREN SAS provides biobased products to replace petroleum-based molecules in France. It offers acetic, propionic, butyric and isobutyric, valeric and isovaleric, and caproic acids. The company's products are used in the flavors and fragrances, lubricants and functional fluids, feed, food, life sciences, and materials science markets. The company was founded in 2012 and is headquartered in Clermont-Ferrand, France.

Full company profile